The DESTINY of Trastuzumab Deruxtecan
DESTINY Breast-03
Background:
HER2 positive breast cancer has seen some really sophisticated drugs come through in this space and the best example of this is the antibody-drug conjugate, trastuzumab-deruxtecan (T-dxd). It is smartly designed to have a high drug-to-antibody ratio of approximately 8 (compared to 3.5 for trastuzumab emtansine (T-DM1))that remains stable ther…
Keep reading with a 7-day free trial
Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.